Several other JAK inhibitors have been developed as immunosuppressive agents for RA and other autoimmune diseases; e.g., upadacitinib (a JAK1 inhibitor) and filgotinib (a JAK1 inhibitor) were demonstrated to be effective as a treatment of RA (37, 38). This evidence concerns the gene JAK1 and autoimmune disease.